Roche's sale of InterMune and Esbriet in the US comes as Boehringer revealed its own follow-up play in the IPF, category, ...

This leaflet answers some common questions about Esbriet. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have ...

This leaflet answers some common questions about Esbriet. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have ...

Caymen Islands-headquartered specialty drug firm Legacy Pharma has announced the completion of the acquisition of InterMune, ...

Esbriet has been playing second fiddle to Ofev in the IPF market, making blockbuster sales of $1.2 billion in 2020 but starting to decline as Boehringer's drug is enjoying buoyant growth.

Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.